Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.

Publication Type:

Journal Article

Source:

Chemotherapy, Volume 58, Issue 1, p.8-18 (2012)

Keywords:

Adult, Aged, Antineoplastic Agents, Breast Neoplasms, Cohort Studies, Costs and Cost Analysis, Cyclophosphamide, Databases, Factual, Doxorubicin, Female, Granulocyte Colony-Stimulating Factor, Health Care Costs, Humans, Middle Aged, Neoplasm Metastasis, NEUTROPENIA, paclitaxel, Retrospective Studies, Risk Factors, Taxoids

Abstract:

The burden of chemotherapy-induced neutropenic complications (CINC) in women with metastatic breast cancer (MBC) is largely unknown and may differ across cancer populations due to variation in the characteristics of patients, their disease and their treatment.